Patents
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2010
12/22/2010CN101919803A Controlled release preparation
12/22/2010CN101919799A Novel sustained-release transdermal medicament delivery system
12/22/2010CN101474411B Anti-tumor prodrug using novel amphipathic hyperbranched polyesters as carrier and preparation method
12/22/2010CN101455641B Anti-cancer medicine liposome preparation sensitive to ray
12/22/2010CN101336915B Medicine combination with antitumor activity
12/21/2010US7855278 antibodies which induces the death of a cell that expresses Stra6 polypeptide; used to prevent or slow down (lessen) the development, growth, or spread of tumor characterized by the overexpression of a PRO10282 polypeptide; chemotherapy
12/21/2010US7855184 Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells and methods of treating ophthalmic and dermatological diseases
12/21/2010US7855183 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
12/21/2010US7855075 Methods of controlling proliferation and differentiation of stem and progenitor cells
12/21/2010US7854935 Herbal therapy for the treatment of asthma
12/21/2010US7854933 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
12/21/2010US7854922 Skin preparation for external use characterized by containing sugar derivative of α, α-trehalose
12/21/2010US7854753 to cellular surfaces without damage; transdermal, transmembrane; with solvent, gelling agent, and photocatalyst has a band gap energy of 2.9 eV to 3.2 e
12/21/2010US7854717 uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors
12/21/2010CA2477885C Pressurised metered dose inhalers containing solutions of beta-2 agonists
12/21/2010CA2464130C Mch antagonists for the treatment of obesity
12/21/2010CA2453823C Dermal therapy using phosphate derivatives of electron transfer agents
12/21/2010CA2444395C Use of nk-1 receptor antagonists against benign prostatic hyperplasia
12/21/2010CA2404594C Agent for prophylaxis and treatment of renal disease
12/21/2010CA2388595C Methods and devices for identifying patterns in biological systems and methods for uses thereof
12/21/2010CA2369895C High affinity inhibitors for target validation and uses thereof
12/21/2010CA2294924C Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
12/21/2010CA2267069C Use of macrophage migration inhibitory factor antagonists for anti-cancer therapy
12/21/2010CA2220753C Novel peptides and compositions which modulate apoptosis
12/21/2010CA2214406C Use of penciclovir for the treatment of human herpes-virus-8
12/16/2010WO2010143661A1 Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity
12/16/2010WO2010143101A1 Use of 1,25-dihydroxyvitamine d3 glycoside in lactating animals.
12/16/2010WO2010143053A1 Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders
12/16/2010WO2010142925A1 Use of alkylglycerols for preparing drugs
12/16/2010WO2010111136A3 Aliskiren modulation of neurogenesis
12/16/2010US20100317854 Novel aminodicarboxylic acid derivatives having pharmaceutical properties
12/16/2010US20100317109 Factor
12/16/2010US20100317003 Novel compositions and methods in cancer with altered expression of kcnj9
12/16/2010US20100316768 Nutritionally Fortified Liquid Composition With Added Value Delivery Systems/Elements/Additives
12/16/2010US20100316708 Novel Pharmaceutical Formulation Containing A Biguanide and a Thiazolidinedione Derivative
12/16/2010US20100316703 Rna interference mediating small rna molecules
12/16/2010US20100316652 Vascular endothelial cell growth factor antagonists
12/16/2010US20100316610 Mutant having uracil phosphoribosyl transferase activity
12/16/2010DE102009024542A1 Zusammensetzungen auf Basis von Chitosan-Oligosacchariden Compositions based on chitosan-oligosaccharides
12/16/2010DE102009019460A1 Use of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor for treatment and/or prevention of coxsackievirus infection and adenoviral infection or diseases caused by coxsackievirus and/or adenovirus e.g. myocarditis and pericarditis
12/16/2010CA2764782A1 Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity
12/15/2010EP2261331A1 Method and kit for detecting proliferative diseases causing sclerosis, preventive and/or remedy for proliferative diseases causing sclerosis and method and kit for identifying substance efficacious in preventing and/or treating proliferative diseases causing sclerosis
12/15/2010EP2261323A1 Feline probiotic lactobacilli
12/15/2010EP2261322A1 Methods of use of probiotic bifidobacteria for companion animals
12/15/2010EP2261321A1 Canine probiotic lactobacilli
12/15/2010EP2261320A1 Canine probiotic lactobacilli
12/15/2010EP2261319A1 Canine probiotic lactobacilli
12/15/2010EP2261256A2 Methods of inhibiting metastasis
12/15/2010EP2260870A2 Treatment of infectious diseases with combinations of a thioxanthene derivative with an anti-infective agent
12/15/2010EP2260869A2 Pharmaceutical product
12/15/2010EP2260867A1 TWEAK receptor agonists as anti-angiogenic agents
12/15/2010EP2260850A2 A2A receptor antogonists for use in the treatment of movement disorders
12/15/2010EP2260846A1 Novel methods for the treatment of cancer
12/15/2010EP2260845A2 Use of polyphenols for the treatment of alopecia
12/15/2010EP2260844A1 Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders
12/15/2010EP2260842A2 Uses of perfluorinated carboylic acid derivatives for the manufacture of a medicament for the modulation of body mass
12/15/2010EP2260838A1 Drug for preventing vascular restenosis and instrument to be embedded in vessel coated with the drug
12/15/2010EP2260837A1 Pharmaceutical compositions for the coordinated delivery of NSAIDs
12/15/2010EP2260833A2 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic
12/15/2010EP2259844A1 Compositions and methods for mucositis and oncology therapies
12/15/2010EP2259800A1 Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
12/15/2010EP2259799A1 Combination of immunomodulator and anti-pathogenic agent
12/15/2010EP2259782A1 Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
12/15/2010EP2259677A2 Systemic purine administration:modulating axonal outgrowth of central nervous system neurons
12/15/2010EP1827495B1 Painkilling association comprising a dihydroimidazopyrazine derivative
12/15/2010EP1720610B1 Alcohol metabolism moderating composition
12/15/2010EP1537146B1 Antibodies binding to anionic phospholipids and aminophospholipids and their use in treating viral infections
12/15/2010EP1444523B1 Screening for hepatitis c virus entry inhibitors
12/15/2010EP1423380B1 Pyrazole-derived kinase inhibitors and uses thereof
12/15/2010EP1404174B1 Anti-infective compositions for treating disordered tissue such as cold sores
12/15/2010EP1395289B1 Treatment of neuropathic pain with a n-methyl-d-aspartate (nmda) receptor antagonists
12/15/2010EP1076703B2 Therapeutic uses of il-17 homologous polypeptides
12/15/2010CN1956720B Combination medication for treating HIV infection
12/15/2010CN1956716B Medicine capable of inhibiting activation of transcription factor KLF5
12/15/2010CN1935134B Combination comprising combretastatin and anticancer agents
12/15/2010CN1933840B Use of a phenothiazine derivative for preventing and/or treating hearing loss
12/15/2010CN1916009B Process for preparing amine platinum complexes
12/15/2010CN1915429B Combinations of the peroxisome proliferator-activated receptor (ppar) activator and sterol absorption inhibitor
12/15/2010CN1883456B Flavor-hidden pharmaceutical granule, preparation method and use thereof
12/15/2010CN1665932B Vectors with modified protease-dependent tropism
12/15/2010CN1547475B Dermal therapy using phosphate derivatives of electron transfer agents
12/15/2010CN101918031A Skin external preparation
12/15/2010CN101917990A Pharmaceutical composition, use of 2-iminopyrrolidine derivative for production of pharmaceutical composition, and kit for treatment or amelioration of heart diseases
12/15/2010CN101917983A Composition for treating sterile inflammation
12/15/2010CN101912612A Dispersible tablet containing fibrate and statin drug and application thereof
12/15/2010CN101912611A Drug composition with anti-tumor effect
12/15/2010CN101564536B Sustained and controlled release preparation for pharmaceutical composition for curing hypertension
12/15/2010CN101267837B Compositions for treatment of systemic mastocytosis
12/15/2010CN101254181B Hypertension-treating medicine combination
12/15/2010CN101138635B Fibrin glue vasodilation agent sustained-release long-acting composition
12/15/2010CN101031321B Perorally administrable antimicrobial composition
12/14/2010USRE41996 Composition and methods for enhancing receptor-mediated cellular internalization
12/14/2010US7851607 Expression vector comprising nucleotide sequences coding porcine reproductive and respiratory syndrome polypeptide for use in generating vaccine to prevent viral infection; immunotherapy
12/14/2010US7851592 Recombinant check point kinase for use in identifying modulator for use in treatment and prevention of cell proliferative disorders
12/14/2010US7851586 Peptides for activation and inhibition of δPKC
12/14/2010US7851458 Cartilage enhancing food supplements and methods of preparing the same
12/14/2010US7851447 Applying at least one chondroitin sulfate proteoglycan-degrading enzyme to the damaged nerve for promoting repair of a damaged nerve
12/14/2010US7850999 For therapy of psoriasis, eczema, ichthyosis, pruritus, dryness and dermatitis, which may cause skin to crack, chap or chafe
12/14/2010US7850995 having a cationic surfactant adsorbed on their surfaces to provide superior adhesion to a biological substrate, e.g., an insect, teeth, bone, nails, chitin, feathers, plants, mucous, skin; drug delivery
12/14/2010US7850990 Compositions for delivery of drug combinations